Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims
Novo Nordisk sues Eli Lilly over GLP-1 drug advertising claims Proactive uses images sourced from Shutterstock Novo Nordisk…
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk
The market for anti-obesity drugs seems to be at risk of calcifying into a dominant duopoly. Eli Lilly…
Wegovy Trial Wins Put Novo Nordisk Obesity Growth Story In Focus
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million…